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A phase II clinical trial of high-dose immunochemother-
apy (HDIT; BEAM/antithymocyte globulin) and autologous
HCT was conducted in patients with highly active RRMS who
had failed conventional therapy to assess if sustained
remission could be induced. Eligibility required an EDSS of
3.0 (moderate disability, fully ambulatory) to 5.5 (severe
disability, ambulatory only 100 meters without aids) and >2
relapses on treatment in previous 18 months. Treatment-
failure was deﬁned as a composite endpoint of 1) mortality
2) relapse 3) new MRI lesions or 4) disability increase >0.5
EDSS points. Adverse events (AE) were recorded according to
NCI-CTCAE v3.0.
25 patients at a median age of 38 (27-53) years were
treatedwith G-CSF tomobilize the autograft; prednisonewas
given at the same time to prevent MS ﬂares. The autograft
was CD34-selected (Baxter, Isolex). One patient withdrew
after mobilization secondary to HIT/pulmonary embolus. 24
patients had HDIT/HCTaccording to protocol. Median follow-
up was 131 (52, 282) weeks. After initially stabilizing, one
patient died from progressive loss of neurological function at
32 months. No patient had delayed recovery of blood counts.
In the 1st year after HDIT, therewere 42 grade 3 and 6 grade 4
non-hematopoietic AE. Grade 4 AE included: one suicide
attempt (with 3 grade 4 AE); hyperuricemia; hypokalemia;
and elevated ALT. In the 2nd year, there were 13 grade 3 and 1
grade 4 non-hematopoietic AE. The 1-year and 2-year
probabilities of event-free survival (i.e. without treatment-
failure) were 95.8% (90% CI: 80.2%-99.2%) and 82.8% (90% CI:
65.0%-92.0%), respectively. Progression-free and relapse-free
survival at 1 year were 100% (90% CI: 100%-100%) and 95.8%
(90% CI: 80.2%-99.2%) and at 2 years were 91.7% (90% CI:
75.7%-97.3%) and 91.7% (90% CI: 75.7%-97.3%), respectively.
The probability of freedom from disease activity detected by
brainMRI was 95.8% (90% CI: 80.2%-99.2%) at both year 1 and
2. In comparison, a randomized clinical trial of placebo vs
natalizumab (Havrdova E et al, Lancet Neurology, 2009)
showed that 7% and 37% of RRMS patients were free of
disease activity (i.e. progression, relapse and MRI) at 2 years,
respectively.T2-weightedMRI scansmeasure disease burden fromMS.
T2 lesion volume was signiﬁcantly reduced by 6 months and
was sustained at 2 years. T1 lesion volumewas increased at 1
year. There was a signiﬁcant loss of brain volume at 6months
but stabilized thereafter.
By ﬂow cytometry, memory CD4 and CD8 T cells
(CD45ROþ) were not completely eliminated from the blood
after in vivo depletion from HDIT. The numbers of CD4 naïve
and memory T cells were not recovered at 1 year. CD4 and
CD8 recent thymic emigrants (CD45RAþ, CD31þ) were
increased at 1 year compared to the nadir at 1 month but did
not completely recover.
HDIT/HCT for highly active RRMS resulted in profound
immunosuppression and induced a high rate of sustained
remissions at 2 years.
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High-dose therapy (HDT) with autologous stem cell
transplantation (ASCT) has recently been shown to be safe
and effective in patients with central nervous system (CNS)
involvement by NHL. Rituximab (R) has been incorporated
into the therapy for CNS NHL, although there is limited
penetration of R across the intact blood brain barrier and into
the cerebrospinal ﬂuid (CSF). 23 patients were treated on
a phase II study using high-dose rituximab in combination
with high-dose cytarabine for autologous stem cell mobili-
zation followed by HDT with thiotepa, busulfan, and cyclo-
phosphamide (TBC), followed by ASCT. Median age was 58
(range 24-73). All patients received 2 doses of R at 1000 mg/
m2/dose on days 1 and 8 of high-dose cytarabine mobiliza-
tion chemotherapy and 2 doses on days -9 and -2 of TBC. 12
patients had primary CNS NHL (7 CR1, 5 relapsed) and 11
patients had secondary CNS involvement from systemic NHL.
All patients were in a chemosensitive partial or complete
remission before mobilization therapy. All patients tolerated
infusions of high dose R without reactions. All patients
achieved neutrophil engraftment (median 9 days, range 8-
12) and platelet engraftment (median 12 days, range 8-40).
The most common toxicities were diarrhea and mucositis.
Two patients developed signiﬁcant neurotoxicity, one who
had previously had whole brain radiation therapy and
another who was thought to develop thrombotic
